Esperion Therapeutics: Delivering On Expectations While Navigating Overhangs

RealPeopleGroup/E+ via Getty Images The best I can say about Esperion Therapeutics, Inc. (NASDAQ:ESPR) the stock is that at least it is (barely) clinging to a trading range. The best I can say about Esperion Therapeutics the company is that the business is still delivering on its promises. Meeting Expectations Esperion reported Q2 2024 earnings last week. While the stock responded with an 8.9% loss (which has almost reversed at the time of writing), the earnings results are what investors should have expect ...